Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (231-240 of 387) with videos related to

Pageof 39
Sort By:
American Journal of Hematology|October 14, 2024
Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screeningSuheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, et al.
American Journal of Hematology|December 6, 2018
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018Alessia Castellino, Jose S Pulido, Patrick B Johnston, et al.
Leukemia & Lymphoma|October 27, 2006
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphomaIvana N M Micallef, Ellen D Remstein, Stephen M Ansell, et al.
Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.
Hematological Oncology|October 28, 2022
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphomaSanjal H Desai, Raphael Mwangi, Alexandra N Smith, et al.
Blood|September 12, 2012
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growthStephen M Ansell, Takashi Akasaka, Ellen McPhail, et al.
Blood Cancer Journal|October 11, 2018
Loss of TNFAIP3 enhances MYD88<sub>L265P</sub>-driven signaling in non-Hodgkin lymphomaKerstin Wenzl, Michelle K Manske, Vivekananda Sarangi, et al.
Mayo Clinic Proceedings|February 13, 2004
Therapeutic options in patients with lymphoma and severe liver dysfunctionIrene M Ghobrial, Robert C Wolf, Denise L Pereira, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2009
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidneyMorie A Gertz, Nelson Leung, Martha Q Lacy, et al.
Blood|September 2, 2011
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndromeAnita D'Souza, Suzanne R Hayman, Francis Buadi, et al.
Pageof 39

Showing results (231-240 of 387) with videos related to

Sort By:
Pageof 39
American Journal of Hematology|October 14, 2024
Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screeningSuheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, et al.
American Journal of Hematology|December 6, 2018
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018Alessia Castellino, Jose S Pulido, Patrick B Johnston, et al.
Leukemia & Lymphoma|October 27, 2006
The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphomaIvana N M Micallef, Ellen D Remstein, Stephen M Ansell, et al.
Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.
Hematological Oncology|October 28, 2022
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphomaSanjal H Desai, Raphael Mwangi, Alexandra N Smith, et al.
Blood|September 12, 2012
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growthStephen M Ansell, Takashi Akasaka, Ellen McPhail, et al.
Blood Cancer Journal|October 11, 2018
Loss of TNFAIP3 enhances MYD88<sub>L265P</sub>-driven signaling in non-Hodgkin lymphomaKerstin Wenzl, Michelle K Manske, Vivekananda Sarangi, et al.
Mayo Clinic Proceedings|February 13, 2004
Therapeutic options in patients with lymphoma and severe liver dysfunctionIrene M Ghobrial, Robert C Wolf, Denise L Pereira, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2009
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidneyMorie A Gertz, Nelson Leung, Martha Q Lacy, et al.
Blood|September 2, 2011
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndromeAnita D'Souza, Suzanne R Hayman, Francis Buadi, et al.
Pageof 39